CytoGenix Inc. Files International Patent Application for Herpes Treatment
TUESDAY , DECEMBER 09, 2003 09:45 AM
HOUSTON, Dec 9, 2003 (BUSINESS WIRE) -- CytoGenix Inc. (OTCBB:CYGX) announces filing of an international patent application for Treatment of Herpes Simplex Virus (HSV)-Related Pathologies Using ssDNA under the international Patent Cooperation Treaty (PCT). This filing is the first step in obtaining patent coverage in countries worldwide including the EU, Brazil, Japan, India and China.
Pre-clinical laboratory studies have shown that CytoGenix's ssDNA expression system greatly reduces viral load in infected cells. The anti-herpes product contains CytoGenix's proprietary ssDNA blended into a commonly used cream base for convenient topical delivery to infected areas of the body.
The US Centers for Disease Control and Prevention (CDC) considers the spread of genital herpes (HSV-2) to be at epidemic levels. One in four American adults has genital herpes. About 95 percent experience the occasional cold sore attack from HSV-1. Worldwide, HSV-2 is the leading cause of neonatal blindness, and recent international studies show that HSV-2 infected persons have a much higher likelihood of HIV infection. In 2002, the worldwide market for herpes related medications exceeded $1.5 billion annually.
Dr. Malcolm Skolnick, CytoGenix's president and CEO, commented, "Increasing the strength of our company's intellectual property through international filings is a crucial part of our business strategy. Patent filings are the first step in successful commercialization of our products as well as our ability to secure regulatory approval, manufacture and market in the U.S. and overseas."
CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and 37 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.
SOURCE: CytoGenix Inc.
CONTACT: CytoGenix Inc., Houston
Juan Ferreira, 407-774-9949
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2003 Business Wire. All rights reserved.
-0-
KEYWORD: TEXAS
INDUSTRY KEYWORD: PHARMACEUTICAL
BIOTECHNOLOGY
PRODUCT
STOCK SYMBOLS: [(cygx)]
Market Data 
Markets 
AI
